Andrew Grieve is the CEO of Zenabis and he joined Business of Cannabis to talk about their agreement to grow Tantalus Labs genetics on contract as well as their stock offering to current shareholders – which has been the topic of conversation among those that follow publicly traded cannabis companies.
Polling Shows Biden’s Cannabis Reform Could Garner 9% Boost in Youth Support
The Biden administration is relying heavily on cannabis reform to drum up support among younger voters ahead of the upcoming...